(Q44101409)

29 November 2017

title

Primary immunosuppression with tacrolimus is associated with a reduction in renal allograft fibrosis compared with neoral therapy (English)

1 reference

29 November 2017

1 reference

Waller JR

1

1 reference

29 November 2017

Murphy GJ

2

1 reference

29 November 2017

Metcalfe MS

3

1 reference

29 November 2017

Sandford RM

4

1 reference

29 November 2017

Pattenden CJ

5

1 reference

29 November 2017

Nicholson ML

6

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 August 2002

1 reference

Transplantation Proceedings

29 November 2017

published in

1 reference

29 November 2017

volume

34

1 reference

29 November 2017

issue

5

1 reference

29 November 2017

page(s)

1587-1588

1 reference

Molecular mechanisms of renal allograft fibrosis

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903033-6

7 January 2021

Differential effects of cyclosporin and tacrolimus on the expression of fibrosis-associated genes in isolated glomeruli from renal transplants

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903033-6

7 January 2021

Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903033-6

7 January 2021

Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: a report of the European Tacrolimus Multicenter Renal Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903033-6

7 January 2021

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903033-6

7 January 2021

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903033-6

7 January 2021

Adverse effects of immunosuppressive drugs on long-term graft outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903033-6

7 January 2021

Ischemic heart disease--major cause of death and graft loss after renal transplantation in Scandinavia

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903033-6

7 January 2021

Tacrolimus/"low-dose" mycophenolate mofetil versus microemulsion cyclosporine/"low-dose" mycophenolate mofetil after kidney transplantation--1-year follow-up of a prospective, randomized clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903033-6

7 January 2021

Outcome of grafts with long-lasting delayed function after renal transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903033-6

7 January 2021

Four-year follow-up of the European Tacrolimus Multicenter Renal Study

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903033-6

7 January 2021

Hyperlipidemia in solid organ transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FS0041-1345%2802%2903033-6

7 January 2021

10.1016/S0041-1345(02)03033-6

Identifiers

DOI

1 reference

29 November 2017

1 reference